The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
First-in-human phase I study of a ROR1-targeting bispecific T-cell engager (NVG-111) shows evidence of efficacy in patients with relapsed/refractory CLL and MCL.
 
Parag Jasani
No Relationships to Disclose
 
William Townsend
Honoraria - Bristol-Myers Squibb/Celgene; Gilead Sciences; Incyte; Roche
Consulting or Advisory Role - Incyte; Roche
Travel, Accommodations, Expenses - Roche; Roche
 
Samir Asher
No Relationships to Disclose
 
Sarrah Tayabali
No Relationships to Disclose
 
David Tucker
Consulting or Advisory Role - Abbvie; Immunovant; Roche
 
Sarah Cook
Employment - NovalGen; Summit Therapeutics
Stock and Other Ownership Interests - Summit Therapeutics
 
Toby Batten
Employment - AstraZeneca/Daiichi Sankyo (I)
 
David Granger
Employment - NovalGen
Stock and Other Ownership Interests - Crescendo Biologics; GlaxoSmithKline; NovalGen
Research Funding - NovalGen
Travel, Accommodations, Expenses - NovalGen
 
Mittal Shah
Employment - NovalGen; UCB
Travel, Accommodations, Expenses - UCB
 
Kieran O'Donovan
Employment - NovalGen
Stock and Other Ownership Interests - NovalGen
Travel, Accommodations, Expenses - NovalGen
 
Amit C. Nathwani
Employment - Freeline Therapeutics; NovalGen
Leadership - Freeline Therapeutics; NovalGen
Stock and Other Ownership Interests - Freeline Therapeutics; NovalGen
Research Funding - Biomarin
Patents, Royalties, Other Intellectual Property - Revenue share agreement with St Jude for LP1-FIX licence Revenue share agreement with UCL for FVIII licence and technology licenced to Freeline and Novalgen